CY1120326T1 - Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους - Google Patents

Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους

Info

Publication number
CY1120326T1
CY1120326T1 CY20181100431T CY181100431T CY1120326T1 CY 1120326 T1 CY1120326 T1 CY 1120326T1 CY 20181100431 T CY20181100431 T CY 20181100431T CY 181100431 T CY181100431 T CY 181100431T CY 1120326 T1 CY1120326 T1 CY 1120326T1
Authority
CY
Cyprus
Prior art keywords
selectin
antibodies
psgl
binding
bind
Prior art date
Application number
CY20181100431T
Other languages
English (en)
Inventor
Scott Rollins
Richard Alvarez
Russell Rother
Ziad S. KAWAR
Rodger P. Mcever
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/974,739 external-priority patent/US8945565B2/en
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of CY1120326T1 publication Critical patent/CY1120326T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

Αποκαλύπτονται αντισώματα τα οποία συνδέονται ειδικά με την Ρ-σελεκτίνη, παρεμποδίζουν τη σύνδεση του PSGL-1 με την Ρ-σελεκτίνη και προκαλούν τη διάσπαση των δημιουργημένων συμπλοκών Ρ-σελεκτίνης/PSGL-1. Στην εφεύρεση ταυτοποιείται μία έως σήμερα μη αναγνωρισμένη, πλησίον του αμινοτελικού άκρου, περιοχή σύνδεσης αντισώματος (ένας στερεοδιαταξικός επίτοπος) της Ρ-σελεκτίνης στην οποία συνδέονται τα αντισώματα (που μπορεί να είναι χιμαιρικά, ανθρώπινα ή εξανθρωποποιημένα αντισώματα για παράδειγμα). Αποκαλύπτονται αντισώματα τα οποία συνδέονται στο στερεοδιαταξικό επίτοπος) της Ρ-σελεκτίνη και τα οποία έχουν διπλή λειτουργία στην παρεμπόδιση της σύνδεσης του PSGL-1 με την Ρ-σελεκτίνη και στην πρόκληση διάσπασης των δημιουργημένων συμπλοκών Ρ-σελεκτίνης/ PSGL-1. Αυτά τα αντισώματα anti-Ρ-σελεκτίνης διπλής λειτουργίας και θραύσματα σύνδεσης αυτών μπορεί να χρησιμοποιηθούν για τη θεραπευτική αντιμετώπιση σε διάφορες οξείες και χρόνιες φλεγμονώδεις και θρομβωτικές διαταραχές και παθήσεις. Αποκαλύπτονται επίσης μέθοδοι διαλογής για την ταυτοποίηση και το χαρακτηρισμό των αντισωμάτων αυτών.
CY20181100431T 2010-12-21 2018-04-24 Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους CY1120326T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/974,739 US8945565B2 (en) 2006-12-01 2010-12-21 Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US201161529682P 2011-08-31 2011-08-31
PCT/US2011/066470 WO2012088265A1 (en) 2010-12-21 2011-12-21 Anti-p-selectin antibodies and methods of their use and identification

Publications (1)

Publication Number Publication Date
CY1120326T1 true CY1120326T1 (el) 2019-07-10

Family

ID=46314448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100431T CY1120326T1 (el) 2010-12-21 2018-04-24 Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους

Country Status (20)

Country Link
EP (2) EP2654781B1 (el)
JP (3) JP6054879B2 (el)
CN (2) CN103874503A (el)
AU (2) AU2011349124B2 (el)
BR (1) BR112013018454A2 (el)
CA (1) CA2822610C (el)
CO (1) CO6781492A2 (el)
CY (1) CY1120326T1 (el)
DK (1) DK2654781T3 (el)
ES (1) ES2676570T3 (el)
HR (1) HRP20180617T1 (el)
HU (1) HUE037992T2 (el)
LT (1) LT2654781T (el)
NO (1) NO2021017I1 (el)
PL (1) PL2654781T3 (el)
PT (1) PT2654781T (el)
RU (1) RU2603097C2 (el)
SI (1) SI2654781T1 (el)
WO (1) WO2012088265A1 (el)
ZA (1) ZA201304685B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662091B1 (en) 2006-12-01 2018-08-22 Selexys Pharmaceuticals Corporation Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
EP2654781B1 (en) * 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
MX2014004025A (es) 2011-10-17 2014-08-01 Univ Muenster Wilhelms Metodos de valoracion de riesgo de lmp y aparatos relacionados.
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
WO2019025847A1 (en) * 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
RU2020132460A (ru) 2018-03-08 2022-04-08 Новартис Аг Применение антитела к p-селектину
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DK0639224T3 (da) * 1992-04-30 2000-10-30 Genentech Inc Varianter i lectindomænet af selectin
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0671951A4 (en) * 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
PL311666A1 (en) * 1993-05-04 1996-03-04 Cytel Corp P-selection antibodies and their application
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2332563A1 (en) 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptides and methods of synthesis and use thereof
US6054927A (en) 1999-09-13 2000-04-25 Eaton Corporation Apparatus and method for sensing an object within a monitored zone
EP2360186B1 (en) * 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
EP2662091B1 (en) * 2006-12-01 2018-08-22 Selexys Pharmaceuticals Corporation Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
US8945565B2 (en) * 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
AU2009246166B2 (en) * 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
EP2654781B1 (en) * 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification

Also Published As

Publication number Publication date
NO2021017I1 (no) 2021-04-12
LT2654781T (lt) 2018-08-10
ES2676570T3 (es) 2018-07-23
BR112013018454A2 (pt) 2017-06-27
JP6054879B2 (ja) 2016-12-27
WO2012088265A1 (en) 2012-06-28
PT2654781T (pt) 2018-05-02
EP2654781A1 (en) 2013-10-30
JP2018199678A (ja) 2018-12-20
EP2654781B1 (en) 2018-01-24
CN108939067A (zh) 2018-12-07
JP6370349B2 (ja) 2018-08-08
JP2017048215A (ja) 2017-03-09
DK2654781T3 (en) 2018-05-28
ZA201304685B (en) 2014-03-26
EP2654781A4 (en) 2015-03-11
SI2654781T1 (sl) 2018-10-30
JP2014510705A (ja) 2014-05-01
CA2822610A1 (en) 2012-06-28
RU2013133412A (ru) 2015-01-27
EP3222635A1 (en) 2017-09-27
CA2822610C (en) 2019-09-03
CN103874503A (zh) 2014-06-18
AU2016262660A1 (en) 2016-12-08
AU2011349124B2 (en) 2016-09-15
AU2011349124A1 (en) 2013-07-18
PL2654781T3 (pl) 2018-09-28
HUE037992T2 (hu) 2018-09-28
RU2603097C2 (ru) 2016-11-20
HRP20180617T1 (hr) 2019-04-05
CO6781492A2 (es) 2013-10-31

Similar Documents

Publication Publication Date Title
CY1120326T1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
CY1122315T1 (el) Συνθεσεις αντισωματων για τη θεραπεια ογκων
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1124723T1 (el) Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
PH12017500890A1 (en) Antibody drug conjugates
CY1119290T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EP4321171A3 (en) Sirp alpha-antibody fusion proteins
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2016012830A (es) Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
MX2015015037A (es) Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
EP4257611A3 (en) Anti-muc1 antibody
AU2018449846A8 (en) An anti-B7-H3 antibody